LONDON, ONTARIO--(CCNMatthews - April 10, 2006) - Stellar Pharmaceuticals Inc. (TSX VENTURE:SLX)(OTCBB:SLXCF) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that Dr. H. Barton Grossman presented clinical results for the Matritech NMP22®BladderChek® Test at the 21st Annual Congress of the European Association of Urology ("EAU") in Paris, the largest Urology conference in Europe. Stellar commenced sales of the NMP22®BladderChek® Test in Canada in October 2004 under an exclusive licensing agreement with Matritech, which runs until December 31, 2008.
